Catalyst Wire Dossier Catalyst Wire Dossier

ibritumomab tiuxetan (Zevalin)

ibritumomab tiuxetan
Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for ibritumomab tiuxetan (Zevalin), covering 2006-09-08 to 2019-10-15. Get the full timeline:

Most recent: Clinical Trial Update: Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma [Phase 2]

See pricing